Complexo Hospitalario Universitario de Lugo
Centro de atención
Imperial College London
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de Imperial College London (9)
2022
2021
-
EAACI Biologicals Guidelines—Recommendations for severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44
2020
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
European Respiratory Journal, Vol. 55, Núm. 1
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042
-
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2009
-
Distribution of espM and espT among enteropathogenic and enterohaemorrhagic Escherichia coli
Journal of Medical Microbiology, Vol. 58, Núm. 8, pp. 988-995